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Abstract
Expression of Mash1 is dysregulated in human neuroblastoma. We have also reported that LMO3 (LIM-only protein 3) has an
oncogenic potential in collaboration with neuronal transcription factor HEN2 in neuroblastoma. However, the precise
molecular mechanisms of its transcriptional regulation remain elusive. Here we found that LMO3 forms a complex with
HEN2 and acts as an upstream mediator for transcription of Mash1 in neuroblastoma. The high levels of LMO3 or Mash1
mRNA expression were significantly associated with poor prognosis in 100 primary neuroblastomas. The up-regulation of
Mash1 remarkably accelerated the proliferation of SH-SY5Y neuroblastoma cells, while siRNA-mediated knockdown of LMO3
induced inhibition of growth of SH-SY5Y cells in association with a significant down-regulation of Mash1. Additionally,
overexpression of both LMO3 and HEN2 induced expression of Mash1, suggesting that they might function as a
transcriptional activator for Mash1. Luciferase reporter assay demonstrated that the co-expression of LMO3 and HEN2
attenuates HES1 (a negative regulator for Mash1)-dependent reduction of luciferase activity driven by the Mash1 promoter.
Chromatin immunoprecipitation assay revealed that LMO3 and HEN2 reduce the amount of HES1 recruited onto putative
HES1-binding sites and E-box within the Mash1 promoter. Furthermore, both LMO3 and HEN2 are physically associated with
HES1 by immunoprecipitation assay. Thus, our present results suggest that a transcriptional complex of LMO3 and HEN2
may contribute to the genesis and malignant phenotype of neuroblastoma by inhibiting HES1 which suppresses the
transactivation of Mash1.
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Introduction
Neuroblastoma is one of the typical childhood cancers and is
originated from sympathetic cell lineage of the neural crest [1,2].
Since the tumor never occurs from the other lineages of the neural
crest, the oncogenic events to cause neuroblastoma might be
strictly regulated in a lineage-specific manner [1,2].
LIM-only protein (LMO) family is composed of four members,
LMO1, LMO2, LMO3 and LMO4. Although LMO proteins
lack a DNA-binding activity, accumulating evidence suggest that
LMO proteins are involved in transcriptional regulation of
specific target genes in collaboration with other transcription
factors [3]. Genetic analyses demonstrated that LMO1 and
LMO2 contribute to the genesis of immature and aggressive T-
cell leukemia [4], whereas LMO4 was implicated in development
of breast cancer [5,6]. Previously, we reported that LMO3 is
expressed at significantly high levels in human unfavorable
neuroblastomas relative to favorable ones, and has an oncogenic
potential in neuroblastoma [7]. LMO3 formed a complex with
neuronal-specific basic helix-loop-helix (bHLH) transcription
factor HEN2, which was also expressed at higher levels in
unfavorable neuroblastoma than favorable one, raising a
possibility that LMO3 may form a complex with HEN2 and
play an important role in genesis and development of neuroblas-
toma through transcriptional regulation of as yet unidentified
target gene(s).
A proneural bHLH transcription factor termed Mash1 plays a
critical role in development of sympathetic neuron and is highly
expressed in neuroblastoma [8,9]. However, its possible contribu-
tion to development of neuroblastoma remains elusive. A bHLH
protein termed HES1 acts as a negative regulator for Mash1 [10].
Intriguingly, studies in Drosophila demonstrated that expression
levels of achaete-scute,aDrosophila homolog of Mash1, are
remarkably induced by a transcriptional complex composed of
Drosophila homolog of LMO (dLMO) and bHLH proteins [11,12].
In this study, we examined whether there could exist functional
relationship between LMO3/HEN2 and Mash1 in neuroblasto-
ma, and found that LMO3/HEN2 attenuates HES1 function and
enhances transactivation of Mash1, leading to aggressive pheno-
type of neuroblastoma.
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High levels of Mash1 expression is associated with poor
outcome of neuroblastoma
Mash1 is constitutively expressed at high levels in neuroblastoma
cell lines and primary neuroblastoma tumors [9,13], however, its
prognostic significance remained elusive. On the other hand,
expression of LMO3 was significantly associated with poor
outcome of the patients [7]. To verify whether a significant
relationship could be observed between expression of LMO3 and
that of Mash1 in primary neuroblastomas, we quantitatively
measured the expression levels of LMO3 and Mash1 mRNA in 100
primary tumors by using a quantitative real-time RT-PCR. The
student’s t-test showed that high expression of LMO3 was
significantly associated with $1 year of age (p=0.036), low
expression of TrkA (p=0.003) and MYCN amplification (p=0.04),
but not with the tumor stage (p=0.17), tumor origin (p=0.083)
and Shimada classification (p=0.082). High expression of Mash1
was significantly associated with advanced tumor stage (p=0.004)
but not with age (p=0.81), TrkA expression (p=0.4), MYCN copy
number (p=0.11), tumor origin (p=0.2) and Shimada classifica-
tion (p=0.45) (Table S1). No significant relationship was observed
between LMO3 and Mash1 mRNA expression levels (the Pearson
correlation coefficient was 0.27). Kaplan-Meier survival curves
indicated that high expression of LMO3 as well as that of Mash1
were significantly associated with poor prognosis (log-rank test,
p=0.006 and p=0.037, respectively; Figure 1). The univariate
analysis according to the Cox proportional hazard model also
indicated that the expression levels of Mash1 and those of LMO3
were significantly associated with poor outcome of the patients
(p=0.048 and p=0.012, respectively; Table S2). The multivariate
Cox proportional hazard model analysis showed that the
expression of Mash1 was significantly independent prognostic
factor from LMO3 expression and age, marginally from MYCN
copy number and origin, but not from the disease stage, and that
the expression of LMO3 was significantly independent prognostic
factor from Mash1 expression, age, the disease stage and origin,
but not from MYCN copy number (Table S2). Thus, the results
obtained from the primary neuroblastomas suggested that both
high mRNA expression of LMO3 and Mash1 were strongly
associated with poor prognoses of the patients with neuroblastoma
but the way of contribution of those seemed to be rather
independent.
Mash1 mediates growth promotion of neuroblastoma
cells
Since Mash1 is highly expressed in primary neuroblastoma [9]
and its higher expression was significantly correlated with poor
prognosis of the patient with neuroblastoma, we then investigated
a possible contribution of Mash1 to neuroblastoma cell growth.
For this purpose, we established three stable Mash1 infectants
derived from the parental SH-SY5Y neuroblastoma cells express-
ing exogenous Mash1 (M-1, M-2 and M-3) and two control vector
alone infectants (V-1 and V-2) by retrovirus-mediated gene
transfer (Figure 2A). As shown in Figure 2B, constitutive
expression of Mash1 in SH-SY5Y cells resulted in a remarkable
increase in their growth rate as compared with the control
infectants, suggesting that Mash1 is involved in regulation of
neuroblastoma cell growth.
As described previously [7], LMO3 has an oncogenic potential
in collaboration with HEN2 in neuroblastoma cells. We then
asked whether or not LMO3 is involved in the Mash1-mediated
enhancement of cell growth. As shown in Figure 2C, siRNA-
mediated knockdown of LMO3 in SH-SY5Y cells was significantly
associated with a down-regulation of Mash1. Additionally, LMO3-
knocked down SH-SY5Y cells showed a slower growth rate than
the control SH-SY5Y cells (Figure 2D), which might be at least in
part due to reduction of Mash1. We conducted the same
experiments by using another cell line SK-N-BE and obtained
the similar results (Figure S1A and B). We then hypothesized that
Mash1 could be one of transcriptional targets of LMO3/HEN2
complex.
LMO3/HEN2 mediate transcriptional induction of Mash1
To address whether Mash1 transcription could be induced by
LMO3/HEN2, SH-SY5Y cells were infected with the indicated
combinations of recombinanta d e n o v i r u s e se n c o d i n gH A -
LMO3 or FLAG-HEN2, and the expression levels of Mash1
were examined by semi-quantitative RT-PCR. Time course
experiments demonstrated that Mash1 is readily detectable in
cells expressing HA-LMO3 alone or in cells co-expressing with
HA-LMO3 and FLAG-HEN2 at 48 h after infection
Figure 1. Kaplan-Meier survival curves of patients with neuroblastomas based on high or low expression of LMO3 (A) or Mash1 (B).
Kaplan-Meier survival curves (n=100) in relation to the expression levels of LMO3 or Mash1 (average cutoff). The patients with high expression of
LMO3 or Mash1 represented significantly poor prognosis than those with its low expression.
doi:10.1371/journal.pone.0019297.g001
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HA-LMO3 and FLAG-HEN2 led to a significant induction of
Mash1. The induction of Mash1 was also observed in SK-N-BE
cells transfected with expression vector HA-LMO3 alone or
HA-LMO3 and FLAG-HEN2 at 72 h after transfection (Figure
S1C). To further confirm these observations, we generated a
luciferase reporter construct carrying human Mash1 promoter
(pluc-Mash1). As shown in Figure 3B, the 59-upstream region of
Mash1 gene contains three putative HES1-binding sites and one
E-box. In both SH-SY5Y cells and SK-N-BE cells, siRNA-
mediated knockdown of human LMO3 reduced promoter
activity of Mash1 in a dose-dependent manner (Figure 3C and
Figure S1D). For luciferase reporter assay without siRNA for
human LMO3, we used mouse neuroblastoma Neuro2a cells
which displayed higher transfection efficiency than human
neuroblastoma cells as examined by GFP staining (data not
shown). Consistent with the above expression studies, LMO3
enhanced luciferase activity driven by Mash1 promoter
( F i g u r e3 D ) .F u r t h e r m o r e ,w ee x a m i n e dt h ee f f e c to fH E N 2
on Mash1 promoter activity in Neuro2a cells, showing that
HEN2 itself inhibited Mash1 promoter activity (Figure 3E).
Intriguingly, however, LMO3 interfered with HEN2 function,
resulting in up-regulation of Mash1 transcription (Figure 3F).
Thus, it is likely that the LMO3 complex including HEN2 and
HES1 regulates transcription of Mash1. The mRNA expression
pattern of LMO3, HEN2, Mash1 and HES1, a negative regulator
of Mash1 transcription, in neuroblastoma cell lines is shown in
Figure S2.
LMO3/HEN2 attenuates HES1-dependent down-
regulation of Mash1
As reported previously [10], HES1 is one of the negative
regulators for Mash1. In accordance with the previous observa-
tions, enforced expression of HES1 dramatically reduced lucifer-
ase activity driven by Mash1 promoter (Figure 4A). The inhibitory
effect of HES1 on Mash1 promoter was stronger than that of
HEN2. To investigate the relationships between HES1 and
LMO3/HEN2 in transcriptional regulation of Mash1,w e
examined effects of HEN2 and LMO3 on HES1-dependent
down-regulation of Mash1 (Figure 4B). The HES1-dependent
inhibition of Mash1 promoter activity was attenuated by co-
expression with FLAG-HEN2 alone or with co-expression with
FLAG-HEN2 plus HA-LMO3. Inhibitory effects of FLAG-HEN2
plus HA-LMO3 on HES1 were larger than that of FLAG-HEN2
alone, suggesting that LMO3/HEN2 complex plays a critical role
in regulation of Mash1 transcription by neutralizing the inhibitory
effect of HES1.
Figure 2. Mash1-mediated growth promotion of neuroblastoma cells. (A) Enforced expression of Mash1. Neuroblastoma SH-SY5Y cells were
infected with empty retrovirus or with retrovirus encoding Mash1 and established two control infectants (V-1 and V-2) and three infectants
expressing Mash1 (M-1, M-2 and M-3). Total RNA was extracted from the indicated cell clones and subjected to RT-PCR to examine expression levels
of Mash1. GAPDH was used as an internal control. (B) Mash1-mediated growth promotion. The indicated infectants were seeded at a density of
3610
4/cell culture dish and allowed to attach overnight. At the indicated time periods, number of viable cells was measured. (C) siRNA-mediated
knockdown of LMO3. SH-SY5Y cells were transfected with empty plasmid (4 mg) or with expression plasmid for siRNA targeting LMO3 (4 mg). Forty-
eight hours after transfection, total RNA was prepared and analyzed for expression levels of LMO3 and Mash1 by RT-PCR. (D) Decreased growth rate in
LMO3-knocked down cells. SH-SY5Y cells (3610
5 cells/cell culture dish) were transfected as in (C). Forty-eight hours after transfection, cells were
transferred into fresh medium. At the indicated time points, number of viable cells was measured.
doi:10.1371/journal.pone.0019297.g002
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LMO3 and/or HEN2 could attenuate the inhibitory effects of
HES1 on Mash1 expression, we performed chromatin immuno-
precipitation (ChIP) assay. Similar to human Mash1 promoter,
mouse Mash1 promoter also contains three putative HES1-binding
sites and one E-box (Figure 4C). Neuro2a cells were transfected
with constant amount of empty plasmid or with expression
plasmid for Myc-HES1 together with or without increasing
amounts of FLAG-HEN2 expression plasmid. Forty-eight hours
after transfection, cross-linked chromatin was prepared and
subjected to ChIP assay. As shown in Figure 4D, the anti-Myc
tag immunoprecipitates contained genomic fragments including
putative HES1-binding sites as well as E-box. The amounts of
Myc-HES1 recruited onto HES1-binding sites and E-box
significantly decreased in the presence of FLAG-HEN2 in a
dose-dependent manner. Additionally, the anti-FLAG immuno-
precipitates contained genomic fragments including putative
HES1-binding sites and E-box in the absence of exogenous
HES1. Co-expression of FLAG-HEN2 and Myc-HES1 inhibited
recruitment of FLAG-HEN2 onto putative HES1-binding sites
and E-box, however, its inhibition was efficiently abrogated by
increasing amounts of FLAG-HEN2. These results suggest that
HEN2 might compete with HES1 in binding to putative HES1-
binding sites and E-box, and thereby inducing the expression of
Mash1.
HEN2 Interacts with HES1 in cells
To examine whether HEN2 could interact with HES1 in cells,
we performed immunoprecipitation experiments. Cell lysates
prepared from Neuro2a cells co-transfected with the indicated
combinations of expression plasmids were subjected to immuno-
precipitation. As clearly shown in Figure 5A, HES1 was co-
immunoprecipitated with FLAG-HEN2. Consistent with these
results, reciprocal experiments showed that the anti-Myc tag
immunoprecipitates contain FLAG-HEN2. In vitro pull-down
assay demonstrated that radio-labeled FLAG-HEN2 is co-
immunoprecipitated with Myc-HES1 (Figure 5B). Additional
immunoprecipitation experiments demonstrated that LMO3 also
forms a stable complex with HES1 (Figure 6A). We have
previously showed that LMO3 forms a stable complex with
HEN2 [7]. To investigate the effect of LMO3 on binding of
HEN2 and HES1 to putative HES1-binding sites and E-box,
Figure 3. LMO3/HEN2-mediated transcriptional induction of Mash1. (A) RT-PCR. SH-SY5Y cells were infected with empty adenovirus or with
the indicated combinations of recombinant adenovirus encoding HA-LMO3 or FLAG-HEN2. At the indicated time points after infection, total RNA was
analyzed for expression levels of LMO3, HEN2 and Mash1 by RT-PCR. GAPDH was used as an internal control. (B) Schematic drawing of human Mash1
promoter. Nucleotide positions were indicated relative to transcriptional initiation site (+1). The putative HES1-binding sites and E-box were depicted
by filled and open boxes, respectively. This genomic fragment was subcloned into appropriate restriction sites of pGL3-Basic Vector to give pluc-
hMash1. (C) siRNA-mediated knockdown of LMO3 reduces the promoter activity of Mash1. SH-SY5Y cells were co-transfected with constant amount
of pluc-Mash1 (100 ng) and pRL-CMV (0.2 ng) in the presence or absence of increasing amounts of expression plasmid for siRNA against human
LMO3 (100 or 400 ng). Forty-eight hours after transfection, cells were lysed and their luciferase activities were measured. (D) LMO3 transactivates
Mash1 promoter. Mouse neuroblastoma Neuro2a cells (1610
5 cells/24-well plate) were co-transfected with constant amount of pluc-hMash1 (100 ng)
and pRL-CMV (0.2 ng) together with or without expression plasmid for HA-LMO3 (150 ng). Forty-eight hours after transfection, cells were lysed and
their luciferase activities were measured. (E) HEN2 inhibits Mash1 promoter activity. Luciferase activities were measured in Neuro2a cells with or
without FLAG-HEN2 (100 ng). (F) LMO3 interferes with negative effect of HEN2 on Mash1 transcription in Neuro2a cells. Luciferase activities were
measured in Neuro2a cells transfected with HA-LMO3 (150 ng), FLAG-HEN2 (100 ng) or both of them.
doi:10.1371/journal.pone.0019297.g003
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together with or without HA-LMO3 expression plasmid and
subjected to ChIP assay. As shown in Figure 6B, the
immunoprecipitates using anti-Myc tag or anti-FLAG tag
antibody contained genomic fragments including putative
HES1-binding sites as well as E-box. The amount of Myc-
HES1 recruited onto HES1-binding sites and E-box decreased in
the presence of HA-LMO3. On the other hand, the amount of
FLAG-HEN2 recruited onto HES1-binding sites and E-box
increased in the presence of HA-LMO3. As shown in Figure 3F,
LMO3 interferes with inhibitory effect of HEN2 on Mash1
expression. These suggest that LMO3 may additively interfere
with the inhibitory effect of HES1 on Mash1 expression by
promoting binding of HEN2 to HES1-binding sites and E-box.
Collectively, it is conceivable that LMO3/HEN2 reduces the
inhibitory effect of HES1 on Mash1 expression through binding to
HES1 and thereby blocking its recruitment onto putative HES1-
binding sites and E-box (Figure 7 and Figure S3).
Discussion
In this study, we found that Mash1 is one of transcriptional
targets of LMO3/HEN2 transcriptional complex, and its
protein product may play an important role in regulation of
neuroblastoma cell growth. As described previously [14], HEN1
as well as its closely related gene HEN2 encodes bHLH-type
transcription factor, which might recognize E-box (59-
CACGTG-39). On the other hand, HES1 has an intrinsic
transcriptional repressor activity [10]. Based on our present
results, adenovirus-mediated expression of LMO3/HEN2
significantly induced Mash1, and HES1-mediated down-regula-
tion of Mash1 promoter activity was recovered by co-expression
of LMO3 and HEN2. Our ChIP analyses indicated that HES1
binds to HES1-recognition sites and E-box within Mash1
promoter in the absence of HEN2, whereas HEN2 efficiently
inhibits the recruitment of HES1 onto HES1-binding sites and
E-box within Mash1 promoter, suggesting that HES1 occupies
HES1-binding sites and E-box to inhibit the promoter activity of
Mash1. On the other hand, HEN2 formed a complex with HES1
and reduced the amounts of HES1 recruited onto HES1-
binding sites as well as E-box to increase the promoter activity
of Mash1 in collaboration with LMO3. T h u s ,i ti sl i k e l yt h a tt h e
balance between intracellular amounts of HES1 and LMO3/
HEN2 might determine expression levels of Mash1,a n dt h e r e b y
regulating neuroblastoma cell growth.
Figure 4. LMO3/HEN2 attenuates HES1-dependent down-regulation of Mash1. (A) Luciferase reporter assay. Neuro2a cells were co-
transfected with constant amount of pluc-hMash1 (100 ng), pRL-CMV (0.2 ng) and expression plasmid for HES1 (50 ng) or HEN2 (50 ng). Forty-eight
hours after transfection, cells were lysed and their luciferase activities were examined. (B) Luciferase reporter assay. Neuro2a cells were co-transfected
with constant amount of pluc-hMash1 (100 ng), pRL-CMV (0.2 ng) and expression plasmid for HES1 (5 ng) in the presence or absence of expression
plasmid for HA-LMO3 (150 ng) together with or without increasing amounts of FLAG-HEN2 expression plasmid (100, 200 or 300 ng). Forty-eight
hours after transfection, cells were lysed and their luciferase activities were examined. (C) Schematic representation of mouse Mash1 promoter. The
canonical HES1-binding sites and E-box were indicated by filled and open boxes, respectively. The positions of primer sets used for chromatin
immunoprecipitation (ChIP) assays were also indicated. (D) ChIP assay. Cross-linked chromatin prepared from Neuro2a cells transfected with the
indicated combinations of expression plasmids was sonicated and immunoprecipitated with normal rabbit serum (NRS), polyclonal anti-Myc tag or
with polyclonal anti-FLAG antibody. The genomic DNA was purified from the immunoprecipitates and amplified by PCR.
doi:10.1371/journal.pone.0019297.g004
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differentiation of sympatho-adrenal precursors of Insm1 mutant
mice although Mash1 is expressed transiently in those cells during
normal neural differentiation [15]. Furthermore, Watt et al.
reported that N-myc positively regulates Mash1 transcription [16].
Therefore, it is possible that in the transcriptional regulation of
Mash1, LMO3 and HEN2 may associate with other nuclear
factors like Insm1 and N-myc besides HES1.
From the developmental point of view, it is known that the
LMO/HEN complex plays an important role in regulating
neuronal differentiation [11,17]. As described [7,18], expression
of LMO3 was highly restricted in adult and fetal brains, and HEN2
was expressed in developing nervous system. Genetic studies
demonstrated that HEN2 participates in proper neural crest-
derived neuroendocrine development and that Mash1 has a
critical role in maintaining neuroendocrine cell phenotype [19,20].
Although LMO3-knockout mice did not exhibit any significant
developmental defects, mice lacking both LMO1 and LMO3 died
after birth, which might be due to neural defects [21]. Since
neuroblastoma is one of the most common childhood solid tumors
of peripheral nervous system arising from as yet unidentified
population of neural crest cells [22] and Mash1 regulates
proliferation of the sympathetic nervous system [23], it is likely
that deregulated expression of Mash1 could contribute to genesis
and development of neuroblastoma, which might be regulated by
LMO3/HEN2 transcriptional complex both in vitro and in vivo.
This LMO3/HEN2-HES1-Mash1 pathway could be the new
future target for developing the anti-neuroblastoma treatment.
Materials and Methods
Ethics Statement
A hundred human neuroblastoma specimens used in the present
study were kindly provided from various institutions and hospitals
in Japan to the Chiba Cancer Center Neuroblastoma Tissue Bank.
Written informed consent was obtained at each institution or
hospital. This study was approved by the Chiba Cancer Center
Institutional Review Board and were conducted according to the
principles expressed in the Declaration of Helsinki.
Tumor Specimens
Tumors were classified according to the International Neuro-
blastoma Staging System (INSS); 25 Stage 1, 13 Stage 2, 33 Stage
3, 23 Stage 4, and 6 Stage4s. Clinical information including age at
diagnosis, tumor origin, Shimada’s histology, prognosis, and
survival months of each patient were obtained. The median
follow-up time for survivors was 35 months (range 3 to 91 months).
Each tumor specimen was assayed for TRKA expression by
Northern blot analysis and for MYCN amplification status by both
fluorescence in situ hybridization (FISH) and real-time quantita-
tive polymerase chain reaction (PCR).
Quantitative Real-time PCR
Total RNA prepared from primary neuroblastomas was reverse
transcribed into cDNA (SuperScript II kit) and subjected to the
real-time PCR. The expression level of GAPDH was measured in
all samples to normalize LMO3 and Mash1 expression according to
Figure 5. Interaction between HEN2 and HES1 in cells. (A) Neuro2a cells were co-transfected with the indicated combinations of expression
plasmids. Forty-eight hours after transfection, cells were lysed and immunoprecipitated with anti-FLAG (left panel) or with anti-Myc tag antibody
(right panel) and the immunoprecipitates were analyzed by immunoblotting with anti-HES1 or with anti-FLAG antibody, respectively. Aliquots of cell
lysates were subjected to immunoblotting with anti-HES1, anti-FLAG or with anti-Myc tag antibody. (B) In vitro pull-down assay. Radio-labeled FLAG-
HEN2 was incubated with cell lysates prepared from Neuro2a cells transfected with Myc-HES1 expression plasmid. The reaction mixture was
immunoprecipitated with normal rabbit serum (NRS) or with polyclonal anti-Myc tag antibody and separated by SDS-PAGE followed by
autoradiography. 1/5 inputs were also shown.
doi:10.1371/journal.pone.0019297.g005
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CA, USA). Oligonucleotide primers and TaqMan probes, which
were labeled at the 59 end with the reporter dye 6-carboxyfluor-
escein (FAM) and at the 39 end with the quencher dye 6-
carboxytetramethylrhodamine (TAMRA), were as follows: LMO3:
forward 59-TCTGAGGCTCTTTGGTGTAACG-39, reverse 59-
CCAGGTGGTAAACATTGTCCTTG-39 and probe 59-FA-
M-AAACTGCGCTGCCTGTAGTAAGCTCATCC-TAMRA-39.
Taqman(R) Gene Expression Assay (Applied Biosystems) was
purchased for Mash1 with Assay ID Hs00269932-m1. Amplification
and detection were done using the ABI Prism 7700 Sequence
Detection System (Applied Biosystems).
Statistical Analysis
Student’s t tests were used to explore possible associations
between LMO3 expression and other factors. The distinction
between high and low levels of LMO3 and Mash1 expression was
based on the mean value. Kaplan-Meier survival curves were
calculated, and survival distributions were compared using the log-
rank test. Cox regression models were used to explore associations
among LMO3 expression, Mash1 expression, age, MYCN amplifi-
cation, tumor origin, Shimada classification and survival. Statis-
tical significance was declared if P,0.05.
Cell Culture and Transfection
SH-SY5Y (human neuroblastoma, ATCC number CRL-2266),
SK-N-BE (human neuroblastoma, ATCC number CRL-2271)
and Neuro2a (mouse neuroblastoma, ATCC number CCL-131)
cells were maintained in RPMI 1640 supplemented with 10%
heat-inactivated fetal bovine serum at 37uC in an atmosphere of
5% CO2 in the air. Cells were transfected with the indicated
expression plasmids using Lipofectamine 2000 transfection reagent
(Invitrogen, Carlsbad, CA, USA) as recommended by the
manufacturer.
Generation of Recombinant Retroviral Vector and
Retrovirus-mediated Gene Transfer
Human Mash1 cDNA was subcloned into the HpaI restriction
site of the pLXSN vector. pLXSN or pLXSN- Mash1 was
transfected into the Q2 packaging cells, and SH-SY5Y cells (1610
6
cells) infected with virus-containing culture medium were cultured
in the medium containing 500 mg/ml G418 (Sigma Chemical Co.,
St. Louis, MO, USA). Two weeks after the selection in G418,
drug-resistant clones were isolated and allowed to proliferate in
medium containing G418.
Reverse Transcription-PCR Analysis
Total RNA was prepared from cultured cells by using the
RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Reverse
transcription was carried out using random primers and
SuperScript II (Invitrogen). Following the reverse transcription,
the resultant cDNA was subjected to PCR-based amplification.
PCR primers used were as follows: human LMO3, forward 59-
ATGCTCTCAGTCCAGCCAGA-39 and reverse 59-TCAGC-
GAACCTGGGGTGCAT-39; human HEN2, forward 59-AAG-
CAGCAGATTCGGACCAT-39 and reverse 59-CTTCTCCT-
CGCGGCTCAG-39; human Mash1, forward 59-GCGTTCAG-
CACTGACTTTTG-39 and reverse 59-CCCCGGGAGACTT-
CTTAGAG-39; human HES1, forward 59-TGAGCCAGCT-
GAAAACACTG-39 and reverse 59-GTCACCTCGTTCATG-
CACTC-3; human glyceraldehydes-3-phosphate dehydrogenase (GAPDH),
forward 59-ACCTGACCTGCCGTCTAGAA-39 and reverse 59-
TCCACCACCCTGTTGCTGTA-39.
Figure 6. LMO3 attenuates binding of HES1 to Mash1 promoter
and promotes that of HEN2. (A) Complex formation between LMO3
and HES1 in cells. Neuro2a cells were transiently transfected with the
indicated combinations of the expression plasmids. Forty-eight hours
after transfection, cell lysates were immunoprecipitated with anti-FLAG
antibody followed by immunoblotting with anti-Myc tag antibody (top
panel). Expressions of FLAG-LMO3 and Myc-HES1 are also shown (lower
panels). (B) ChIP assay. Cross-linked chromatin prepared from Neuro2a
cells transfected with the indicated combinations of expression
plasmids was sonicated and immunoprecipitated with normal rabbit
serum (NRS), polyclonal anti-Myc tag or with polyclonal anti-FLAG
antibody. The genomic DNA was purified from the immunoprecipitates
and amplified by PCR.
doi:10.1371/journal.pone.0019297.g006
Figure 7. Model for LMO3 and HEN2 cooperation in transcrip-
tional regulation of Mash1 in Neuroblastoma. HES1 binds to
HES1 binding sites and E-box on Mash1 promoter and represses Mash1
transcription. LMO3 inhibits recruitment of HES1 onto HES1-binding
sites and E-box on Mash1 promoter by forming complex with HES1.
HEN2 interferes with recruitment of HES1 onto HES1-binding sites and
E-box on Mash1 promoter by forming complex with HES1 and
competing with HES1 in binding to these sites. LMO3 promotes
recruitment of HEN2 onto HES1-binding sites and E-box on Mash1
promoter by forming complex with HEN2 but inhibits negative effects
of HEN2 on Mash1 promoter. Thereby expression of Mash1 is up-
regulated.
doi:10.1371/journal.pone.0019297.g007
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Human LMO3 RNAi vector was made using the original
plasmid that is gift from A.K. Munirajan (Chiba Cancer Center
Research Institute). The targeted sequence is 59- GTAG-
TAAGCTCATCCCTGC -39. RNAi construct was transiently
transfected into SH-SY5Y cells using Lipofectamine 2000
transfection reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instruction.
Generation of Recombinant Adenoviral Vector
For construction of the adenovirus expression vector, an HA-
tagged human LMO3 cDNA or a FLAG-tagged human HEN2
cDNA were inserted into the shuttle vector pHMCMV6 [24].
Efficient construction of a recombinant adenovirus vector by an
improved in vitro ligation method [25]. The resultant shuttle vector
was digested with I-CeuI and PI-SceI and subcloned into the
identical restriction sites of the adenovirus expression vector
pAdHM4. The recombinant adenovirus construct was digested
with PacI and transfected into 293 cells to generate recombinant
adenovirus.
Luciferase Reporter Assay
The reporter plasmid contains a 1.2-kb fragment of the human
Mash1 promoter that was subcloned into the pGL3-Basic Vector
(Promega Corp., Madison, WI, USA) upstream of the luciferase
reporter gene. Cells were seeded in triplicates into 24-well plates
(1610
5 cells/well) 24 h prior to transfection. Cells were cotrans-
fected with 100 ng of the reporter plasmid, 0.2 ng of pRL-CMV
encoding Renilla luciferase cDNA, 5 ng of rat HES1expression
vector, 150 ng of HA-LMO3, 100 to 300 ng of FLAG-HEN2
expression vectors. Total amount of plasmid DNA per transfection
was kept constant with pcDNA3 (Invitrogen). At 48 h after
transfection, luciferase activity was measured by a Dual-Luciferase
Reporter Assay System (Promega), and the transfection efficiency
was standardized against Renilla luciferase activity.
Chromatin Immunoprecipitation (ChIP) Assays
ChIP assay was performed according to the protocol recom-
mended by Upstate (Lake Placid, NY, USA). Cross-linked
chromatin prepared from Neuro2a cells transfected with expres-
sion plasmids was sonicated and immunoprecipitated with normal
rabbit serum (NRS), polyclonal anti-Myc tag (Medical &
Biological Laboratories, Nagoya, Japan) or with polyclonal anti-
FLAG (Sigma, St. Louis, MO, USA) antibody. The genomic DNA
was purified from the immunoprecipitates and amplified by PCR.
The primers used to amplify the mouse Mash1 promoters were
as follows: HES1 binding site (PCR-1), forward 59-ATTTCTA-
GAGCCACCCCCTG-39 and reverse 59-TTGTTGCAGTGCG-
TGCGCC-39; HES1 binding site (PCR-2), forward 59-
AGTGCGCTCGGCACTGACTT-39 and reverse 59-CGCG-
GTTGGCTTCGGGAGCC-39; E-box (PCR-3), forward 59-
ATGGAGAGTTTGCAAGGAGC-39 and reverse 59-CAGCCC-
CACGCGCAGCCCTG-39.
Western Blot Analysis and Immunoprecipitation
After transfection, Neuro2a cells were placed on ice, washed
twice with phosphate-buffered saline, and lysed in lysis buffer
containing 25 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM
KCl, 1% TritonX-100, 1 mM phenylmethylsulfonyl fluoride and
protease inhibitor mixture (Sigma). Lysates were placed on ice for
30 min, sonicated briefly, and clarified by centrifugation at
15,0006 g for 5 min at 4uC. Protein concentrations of the
supernatants were determined by using a Bio-Rad protein assay.
For immunoblot analysis, proteins were resolved by sodium
dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE)
and electrotransferred onto a nitrocellulose membrane. The
membrane filter was blocked with 2% gelatin in Tris-buffered
saline (TBS) for 3 h at room temperature and then incubated with
a primary antibody including monoclonal anti-rat HES1 (Medical
& Biological Laboratories, Nagoya, Japan), monoclonal anti-
FLAG (M2; Sigma) or monoclonal anti-Myc (9B11; Cell Signaling
Technology, Danvers, MA, USA) antibody over night at 4uC. The
membrane filter was then incubated with a goat anti-mouse
secondary antibody conjugated to horseradish peroxidase (Cell
Signaling Technology, Danvers, MA, USA) or goat anti-rat
secondary antibody conjugated to horseradish peroxidase (Beck-
man Coulter, Marseille, France) for 1 h at room temperature and
bound secondary antibody was detected by enhanced chemilumi-
nescence (Amersham Pharmacia Biotech) according to the
manufacturer’s protocol. For Immunoprecipitation, equal
amounts of cell lysates (2 mg) were precleared with 25 mlo f
protein G-Sepharose (Amersham Bioscience, Uppsala, Sweden).
After brief centrifugation, immunoprecipitation was carried out by
incubating the supernatant with anti-FLAG polyclonal (Sigma, St.
Louis, MO, USA) or anti-Myc tag polyclonal antibody (Medical &
Biological Laboratories, Nagoya, Japan) over night at 4uC.
Immunocomplexes were precipitated with protein G-Sepharose
beads (Amersham Biosciences) for 3 hours at 4uC. The immuno-
precipitated proteins were resolved by SDS-PAGE and analyzed
by Western blotting.
In vitro Pull-down Assay
Radio-labeled FLAG-HEN2 was generated by using in vitro
transcription/translation system (Promega) and incubated with cell
lysates prepared from Neuro2a cells transfected with Myc-HES1
expression plasmid. The reaction mixture was immunoprecipitat-
ed with normal rabbit serum (NRS) or with polyclonal anti-Myc
tag antibody (Medical & Biological Laboratories, Nagoya, Japan)
and separated by SDS-PAGE followed by autoradiography.
Data Analysis and Statistics
All values for statistical significance represent mean 6 SD. We
carried out comparisons between means using the Student’s t-test.
Statistical significance implies P,0.05.
Supporting Information
Figure S1 Mash1-mediated growth promotion and
LMO3/HEN2-mediated transcriptional induction of
Mash1 in SK-N-BE cells. (A) siRNA-mediated knockdown of
LMO3. SK-N-BE cells were transfected with empty plasmid (4 mg)
or with expression plasmid for siRNA targeting LMO3 (4 mg).
Forty-eight hours after transfection, total RNA was prepared and
analyzed for expression levels of LMO3 and Mash1 by RT-PCR.
(B) Decreased growth rate in LMO3-knocked down cells. SK-N-
BE cells (4.5610
3 cells/well, 96 well culture plate) were transfected
with empty plasmid (0.2 mg) or with expression plasmid for siRNA
targeting LMO3 (0.2 mg). Forty-eight hours after transfection, cells
were transferred into fresh medium. At the indicated time points,
cell growth was measured by MTT assay (Cell Counting Kit-8,
DOJINDO). (C) RT-PCR. SK-N-BE cells were transfected with
pcDNA3 empty plasmid or with the indicated combinations of
expression plasmid HA-LMO3 or FLAG-HEN2. At 72 hours
after transfection, total RNA was analyzed for expression levels of
LMO3, HEN2 and Mash1 by RT-PCR. GAPDH was used as an
internal control. (D) siRNA-mediated knockdown of LMO3
reduces the promoter activity of Mash1. SK-N-BE cells were co-
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pRL-CMV (0.2 ng) in the presence or absence of increasing
amounts of expression plasmid for siRNA against human LMO3
(100 or 400 ng). Forty-eight hours after transfection, cells were
lysed and their luciferase activities were measured.
(TIF)
Figure S2 Expression of LMO3, HEN2, Mash1 or HES1
in neuroblastoma cell lines. Semiquantitative RT-PCR
analysis for expression of LMO3, HEN3, Mash1 or HES1 in
neuroblastoma cell lines is performed under linear amplification
conditions. Expression of GAPDH is shown as a control.
(TIF)
Figure S3 Model for LMO3 and HEN2 cooperation in
transcriptional regulation of Mash1 in Neuroblastoma.
(A) HES1 binds to HES1 binding sites and E- box on Mash1
promoter and represses Mash1 transcription. (B) LMO3 inhibits
recruitment of HES1 onto HES1-binding sites and E-box on
Mash1 promoter by forming complex with HES1, and thereby
inducing the expression of Mash1. (C) HEN2 interferes with
recruitment of HES1 onto HES1-binding sites and E-box on
Mash1 promoter by forming complex with HES1 and competing
with HES1 in binding to these sites. HEN2 also represses Mash1
transcription but the inhibitory effects are weaker than that of
HES1, and so up-regulating transcription of Mash1. (D) LMO3
promotes recruitment of HEN2 onto HES1-binding sites and E-
box on Mash1 promoter by forming complex with HEN2 but
inhibits negative effects of HEN2 on Mash1 promoter. Further-
more, LMO3 inhibits recruitment of HES1 onto HES1-binding
sites and E-box on Mash1 promoter, and so Mash1 may be more
highly expressed.
(TIF)
Table S1 Correlation between expression of LMO3 or Mash1
and other prognostic factors (Student’s t-test).
(PDF)
Table S2 Univariate and multivariate analyses of Mash1 and
LMO3 mRNA expression as well as other prognostic factors in
primary neuroblastomas.
(PDF)
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